[{"address1": "91 43rd Street", "address2": "Suite 110", "city": "Pittsburgh", "state": "PA", "zip": "15201", "country": "United States", "phone": "412 432 1500", "website": "https://predictive-oncology.com", "industry": "Software - Infrastructure", "industryKey": "software-infrastructure", "industryDisp": "Software - Infrastructure", "sector": "Technology", "sectorKey": "technology", "sectorDisp": "Technology", "longBusinessSummary": "Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D culture models used in drug development. Its Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. Predictive Oncology Inc. has a strategic collaboration with Every Cure to identify and prioritize drugs for repurposing. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Pittsburgh, Pennsylvania.", "fullTimeEmployees": 23, "companyOfficers": [{"maxAge": 1, "name": "Mr. Raymond F. Vennare", "age": 71, "title": "CEO & Chairman", "yearBorn": 1953, "fiscalYear": 2024, "totalPay": 525000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joshua  Blacher CPA, M.B.A.", "age": 51, "title": "Interim Chief Financial Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 453940, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas  McLaughlin", "title": "Chief Investment Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sara  Turken J.D.", "title": "Senior VP & General Counsel", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lawrence J. DeLucas D.Sc, O.D, Ph.D.", "title": "Senior Vice President of Biologics", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Arlette H. Uihlein FCAP, M.D.", "title": "Senior VP of Translational Medicine & Drug Discovery and Medical Director", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 0.0, "open": 5.95, "dayLow": 5.45, "dayHigh": 6.0, "regularMarketPreviousClose": 0.0, "regularMarketOpen": 5.95, "regularMarketDayLow": 5.45, "regularMarketDayHigh": 6.0, "payoutRatio": 0.0, "beta": 1.353, "forwardPE": -49.583332, "volume": 52200, "regularMarketVolume": 52200, "averageVolume": 108886, "averageVolume10days": 47407, "averageDailyVolume10Day": 47407, "bid": 5.82, "ask": 6.02, "bidSize": 100, "askSize": 100, "marketCap": 20191426, "fiftyTwoWeekLow": 3.88, "fiftyTwoWeekHigh": 45.899998, "allTimeHigh": 5680540.0, "allTimeLow": 3.88, "priceToSalesTrailing12Months": 12.131303, "fiftyDayAverage": 6.791, "twoHundredDayAverage": 12.55971, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": "NaN", "currency": "USD", "tradeable": false, "enterpriseValue": 21902372, "profitMargins": 0.0, "floatShares": 1833008, "sharesOutstanding": 3393516, "sharesShort": 68791, "sharesShortPriorMonth": 42177, "sharesShortPreviousMonthDate": 1761868800, "dateShortInterest": 1764288000, "sharesPercentSharesOut": 0.020299999, "heldPercentInsiders": 0.049250003, "heldPercentInstitutions": 0.00153, "shortRatio": 2.3, "shortPercentOfFloat": 0.0233, "impliedSharesOutstanding": 3393517, "bookValue": -100.942, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -84620600, "trailingEps": -141.32, "forwardEps": -0.12, "lastSplitFactor": "1:15", "lastSplitDate": 1759190400, "enterpriseToRevenue": 13.159, "enterpriseToEbitda": -2.028, "52WeekChange": -0.5304617, "SandP52WeekChange": 0.19362879, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "POAI", "underlyingSymbol": "POAI", "shortName": "Predictive Oncology Inc.", "longName": "Axe Compute Inc.", "firstTradeDateEpochUtc": 1270819800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "ede503d8-4ee2-3426-a158-08a863c76bc5", "messageBoardId": "finmb_50261774", "gmtOffSetMilliseconds": -18000000, "currentPrice": 5.95, "recommendationKey": "none", "totalCash": 181667, "totalCashPerShare": 0.054, "ebitda": -10798828, "totalDebt": 1891827, "quickRatio": 0.003, "currentRatio": 0.014, "totalRevenue": 1664407, "revenuePerShare": 2.951, "returnOnAssets": -1.2880299, "grossProfits": 814043, "freeCashflow": 70531296, "operatingCashflow": -7882418, "revenueGrowth": -0.074, "grossMargins": 0.48909, "ebitdaMargins": 0.0, "operatingMargins": -906.54065, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2026-01-10"}]